Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits

Cynthia K Hahn; Adam C Palmer; David M Weinstock

doi:10.1016/j.ccell.2023.08.005

Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits

Cancer Cell. 2023 Oct 9;41(10):1696-1698. doi: 10.1016/j.ccell.2023.08.005. Epub 2023 Sep 28.

Authors

Cynthia K Hahn¹, Adam C Palmer², David M Weinstock³

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
² Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
³ Merck & Co., Rahway, NJ, USA. Electronic address: david.weinstock@merck.com.

PMID: 37774696
DOI: 10.1016/j.ccell.2023.08.005

Abstract

Zhang et al. report a randomized phase 2 trial for diffuse large B cell lymphoma (DLBCL) that compared standard of care (R-CHOP) to R-CHOP combined with one of 5 agents matched to an individual lymphoma's genetics. Overall, the matching strategy significantly outperformed R-CHOP, laying the foundation for a paradigm-shifting phase 3 trial.

Publication types

Clinical Trial, Phase II
Randomized Controlled Trial
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / genetics
Prednisone / therapeutic use
Rituximab / therapeutic use
Treatment Outcome
Vincristine / therapeutic use

Substances

Rituximab
Cyclophosphamide
Vincristine
Prednisone
Doxorubicin